**Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) eModule Series for Healthcare Professionals**

**Module 4 – Knowledge Check**

1. What is the volume of a dose of reconstituted Nimenrix®?
	1. 0.2 ml
	2. 0.5 ml
	3. 0.8 ml
	4. 1.0 ml

 ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: A booster dose of Nimenrix® is only appropriate for individuals who have previously received primary vaccination with Nimenrix®.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: Nimenrix® is a conjugate vaccine that can help protect against the *N. meningitidis* serogroups A, C, W-135 and Y.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Nimenrix® has demonstrated immunogenicity in which age groups?
	1. Babies (<6 weeks)
	2. Babies and toddlers (≥6 weeks – 23 months)
	3. Children (2 – 10 years)
	4. Adolescents (11 – 17 years)
	5. Adults (18 – 55 years)
	6. Elderly (≥56 years)

 ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the following are very common (≥1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
	1. Irritability
	2. Drowsiness
	3. Dizziness
	4. Fever
	5. Insomnia
	6. Loss of appetite

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the following are common (≥1/100 to <1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
	1. Diarrhoea
	2. Pruritus
	3. Vomiting
	4. Myalgia
	5. Hypoaesthesia
	6. Insomnia

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: Vaccination should not be deferred in the presence of a minor infection such as a cold.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**ANSWERS**

1. What is the volume of a dose of reconstituted Nimenrix®?
	1. 0.2 ml
	2. 0.5 ml
	3. 0.8 ml
	4. 1.0 ml

Answer: b1

1. True or false: A booster dose of Nimenrix® is only appropriate for individuals who have previously received primary vaccination with Nimenrix®.

Answer: false1

1. True or false: Nimenrix® is a conjugate vaccine that can help protect against the *N. meningitidis* serogroups A, C, W-135 and Y.

 Answer: true1

1. Nimenrix® has demonstrated immunogenicity in which age groups?
	1. Babies (<6 weeks)
	2. Babies and toddlers (≥6 weeks – 23 months)
	3. Children (2 – 10 years)
	4. Adolescents (11 – 17 years)
	5. Adults (18 – 55 years)
	6. Elderly (≥56 years)

 Answer: b, c, d, e, f1

1. Which of the following are very common (≥1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
	1. Irritability
	2. Drowsiness
	3. Dizziness
	4. Fever
	5. Insomnia
	6. Loss of appetite

Answer: a, b, d, f1

1. Which of the following are common (≥1/100 to <1/10) side effects that have been reported following Nimenrix® vaccination in age groups 6 weeks to 55 years? *Select all that apply*
	1. Diarrhoea
	2. Pruritus
	3. Vomiting
	4. Myalgia
	5. Hypoaesthesia
	6. Insomnia

Answer: a, c1

1. True or false: Vaccination should not be deferred in the presence of a minor infection such as a cold.

Answer: True1

**Reference**

1. Pfizer Limited. Nimenrix® Summary of Product Characteristics. February 2021.

